Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 9Terminated 4Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Plasma cell 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × L-BLP25 × Clear all
NCT02049151 2017-08-23

START2

EMD Serono

Phase 3 Terminated
35 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Merck KGaA, Darmstadt, Germany

Phase 3 Terminated
285 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT00925548 2014-07-24

STRIDE

EMD Serono

Phase 3 Terminated
16 enrolled 6 charts
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡